Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
In daily practice, several scales are used to evaluate patients with small vessel diseases of the brain (SVD). However, these scales exclude key symptoms such as apathy and mood disorders observed in SVD. Furthermore, the use of a combination of scales does not allow neither a very sensitive assessment of clinical changes, neither an overall assessment of a patient's outcome.
Moreover, there is no scale dedicated to cognitive, emotional and behavioural complaints in patients with SVD. These patients are evaluated with scales used in neurodegenerative diseases such as Alzheimer's disease and frontotemporal dementia. These are scales that have been developed in the elderly and they are not sensitive to minor complaints. It is needful to develop scales adapted to patients with SVD in order to understand the consequences of the disease symptoms on their daily life at inclusion and during follow-up.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Develop a Global Clinical Severity Scale in Patients with cerebral SVD | The primary outcome is to develop this scale, thus precise definition of the scale is not available | 3 years post-inclusion |
| Measure | Description | Time Frame |
|---|---|---|
| Internal validity of each scale | To analyze correlations between items, scale structure, o floor and ceiling effects and profiles of missing data | 3 years post-inclusion |
| Intra evaluator reliability |
Not provided
Inclusion Criteria:
Optional:
• Presence of informative companion in contact with the patient at least once every 15 days
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients with small vessel disease will be recruited from the Department of Neurology at Lariboisière Hospital. The study will be proposed to patients when they come to Lariboisière Hospital for hospitalization (full hospitalization or day hospitalization) or consultation.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Sophie TEZENAS DU MONTCEL | Contact | +33142160582 | sophie.tezenas@aphp.fr | |
| Matthieu Resche-Rigon | Contact | +33142499742 |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Lariboisiere hospital | Recruiting | Paris | 75010 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D059345 | Cerebral Small Vessel Diseases |
| ID | Term |
|---|---|
| D002561 | Cerebrovascular Disorders |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| 3 years post-inclusion |
| Inter-evaluator reliability | 3 years post-inclusion |
| Scale validity | 3 years post-inclusion |
| Scale sensitivity to change | To determine clinically important minimal difference. | 3 years post-inclusion |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |